The US Food and Drug Administration (FDA) has remained lively and on prime of the COVID-19 pandemic. Over the course of the previous seven days, the company has launched scientific discoveries, issued authorizations for COVID-19 assessments, and taken motion in opposition to corporations falsely claiming to supply cures.
Virus therapy acceleration
The FDA has posted an up to date Coronavirus Treatment Acceleration Program (CTAP) webpage. The webpage offers details about CTAP’s objective, technique and operations.
The current revisions embrace a dashboard depicting essential statistics associated to the event of potential COVID-19 therapeutics. Additionally, the useful resource shares are key steerage and hyperlinks for therapeutic builders, researchers, sufferers and customers.
Antibody response discovery
This week, FDA scientists reported they’ve recognized particular areas of the ‘spike proteins’ on the floor of the COVID-19-casuing virus that look like key to triggering robust protecting antibody responses in rabbits uncovered to the virus. The virus makes use of one a part of the spike protein to connect to a cell and one other to fuse with the cell membrane, enabling the virus to contaminate the cell.
The scientists studied antibody response to SARS-CoV-2 spike proteins, which might assist inform vaccine design by rising our understanding of the assorted triggered antibody responses.
The spike glycoprotein is the important thing goal for protecting antibodies in opposition to each SARS-CoV-2 (the COVID-19 virus) and the associated SARS-CoV-1 virus, in accordance with company scientists. Therefore, many vaccine candidates that set off antibodies — in opposition to particular areas on the SARS-CoV-2 spike protein — are being investigated.